Pangaea Ventures

Pangaea Ventures Ltd. is a venture capital firm based in Vancouver, Canada, founded in 2000. The firm specializes in investing in early-stage and growth-stage companies, focusing predominantly on advanced materials, including energy, electronics, health, and sustainability. It targets investments in sectors such as chemistry, material science, nanotechnology, and clean technology, with an emphasis on solutions that address significant global challenges like climate change, food and water insecurity, and health issues. Pangaea Ventures typically invests between CAD0.5 million and CAD10 million, acquiring significant minority stakes and often seeking board representation in its portfolio companies. The firm is committed to being a lead investor and collaborates with co-investors when appropriate. Pangaea Ventures primarily focuses on companies located in North America, Europe, and Russia, and intentionally avoids investments in pharmaceuticals and weapons.

Sarah Applebaum

Partner

Chris Erickson

General Partner

Chris Erikson JD

Founding General Partner

Janelle Goulard

Partner, Health Investment

Andrew Haughian

General Partner

Leonid Molchanovsky

General Partner

Tara Nietzold

Associate

Purnesh Seegopaul

General Partner

David Weekes

Associate

Calvin Yee

Partner

Past deals in British Columbia

Aspect Biosystems

Series A in 2020
Aspect Biosystems Ltd. is a biotechnology company based in Vancouver, Canada, focused on 3D bioprinting and tissue engineering. Founded in 2013, it develops bioprinted tissue therapeutics aimed at transforming disease treatment. The company utilizes proprietary microfluidic 3D bioprinting technology to create physiologically relevant living tissues, allowing for precise control over biomaterial composition and structure during fabrication. Aspect Biosystems offers contract testing services using its 3DAirwayALI human tissue model, catering to pharmaceutical firms and academic institutions engaged in research related to respiratory diseases. Through partnerships with leading researchers and industry innovators, the company aims to address significant challenges in regenerative medicine and advance the understanding of human tissue creation for medical research and therapeutic discovery.

Aspect Biosystems

Venture Round in 2017
Aspect Biosystems Ltd. is a biotechnology company based in Vancouver, Canada, focused on 3D bioprinting and tissue engineering. Founded in 2013, it develops bioprinted tissue therapeutics aimed at transforming disease treatment. The company utilizes proprietary microfluidic 3D bioprinting technology to create physiologically relevant living tissues, allowing for precise control over biomaterial composition and structure during fabrication. Aspect Biosystems offers contract testing services using its 3DAirwayALI human tissue model, catering to pharmaceutical firms and academic institutions engaged in research related to respiratory diseases. Through partnerships with leading researchers and industry innovators, the company aims to address significant challenges in regenerative medicine and advance the understanding of human tissue creation for medical research and therapeutic discovery.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.